Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation Leukemia (2005) We read with great interest the recent clinical score developed by Gallardo et al 1 for predicting the outcome after HLA-identical sibling donor allogeneic stem cell transplantation (SCT) in myeloid malignancies. However, we were somewhat surprised that cytogenetic variables were not taken into account as part of the analysis of SCT outcomes in acute myeloid leukemia (AML). Several studies over recent years have clearly defined cytogenetics as a major determinant of relapse risk and survival in AML, including post-SCT. 2, 3 There is now general consensus that cytogenetic risk groups be used as the basis of selecting treatment strategies in AML, including allogeneic SCT. 4, 5 In general, patients with good-risk cytogenetics are recommended for SCT only after relapse, and patients with poor-risk7inter-mediate-risk cytogenetics considered for HLA-identical sibling allogeneic SCT in first CR. Thus, we believe that analysis of SCT outcomes in AML without including cytogenetic information has limited generalised applicability.
Using the clinical score developed by Gallardo et al, we also analysed the results of HLA-matched sibling donor allogeneic SCT performed at our institution for adult patients with AML between 1987 and 2004. Score 1 was defined as the presence of no risk factors (SCT in first complete remission (CR), age o30 years and absence of sex mismatch, defined as female donor to male recipient), score 2 as SCT in first complete remission7age 430 and/or sex mismatch, score 3 as SCT beyond first CR7age430 years or sex mismatch, and score 4 the presence of all three risk factors. Overall survival (OS) and disease-free survival (DFS) were calculated by the Kaplan and Meier method, with comparison between groups performed by the log-rank test.
In total, 116 transplants had been performed, with complete data available in 114. This included 14 cases with score 1, 46 cases with score 2, 31 cases with score 3, and 23 cases with show the actuarial OS and DFS, respectively, based on patient's score. As can been seen, patients with score 2 actually had superior OS and DFS in comparison to those with score 1, as did patients with score 4 in comparison to score 3. There was no significant difference in OS (P ¼ 0.07) or DFS (P ¼ 0.18) between patients with scores 1 and 4. As such, we were unable to validate Gallardo et al's clinical score for predicting outcome after HLA-identical sibling donor allogeneic SCT in AML. While we applaud the efforts of Gallardo et al in development of such a score, we believe that for such scoring systems to have relevance, analysis of cytogenetic information must also be included. The (12;21)(p13;q22) translocation resulting in TEL/AML1 gene fusion is generally associated with a good prognosis and a high cellular sensitivity to L-asparaginase (L-Asp). 1,2 L-Asp hydrolyses asparagine and glutamine resulting into cellular depletion of these amino acids.
GA
Krejci et al 3 studied changes in cell proliferation of t(12;21)-positive and t(12;21)-negative ALL cells after exposure to L-Asp. In correspondence with our data, 2 their data indicate that leukemic cells are able to upregulate asparagine synthetase (AS) gene expression upon nutrient stress induced by L-Asp. In addition, our work and Krejci's work show that AS was unexpectedly higher expressed in t(12;21)-positive ALL cells compared to t(12;21)-negative patients. These important findings contradict the general hypothesis that resistance to L-Asp is caused by an elevated basic cellular level of AS and/or by the selective ability of only resistant cells to rapidly induce the expression of the AS gene upon L-Asp exposure, 4 since t(12;21)-positive ALL cells are more sensitive to L-Asp compared to t(12;21)-negative ALL patients.
1,2 Besides induction of expression of AS, Krejci et al observed that L-Asp selectively prevents S-phase entry of a t(12;21)-positive cell line, but not a t(12;21)-negative cell line. Since AML1 is involved in the regulation of the G 1 to S cell cycle transition 5, 6 and TEL/AML1 converts AML1 from functioning as a transcriptional activator to a transcriptional repressor, 7 we investigated whether t(12;21)-positive patients already show this cell cycle arrest at initial diagnosis, independent from L-Asp treatment.
To this aim, the cell cycle of 75 t(12;21)-positive and 116 t(12;21)-negative ALL patients at initial diagnosis obtained from the DCOG was analysed by propidium-iodide staining of nuclei, as measured by flow cytometry (Figure 1 ). The percentage of cells in S phase is lower in t(12;21)-positive ALL (median: 6.8%) compared to t(12;21)-negative ALL (median: 8.5%; P ¼ 0.017). This finding might also contribute to our and Krejci's observations that AS expression is higher in t(12;21)-positive ALL compared to t(12;21)-negative ALL at diagnosis, as AS was described to be compensationally increased when cells could not proceed through the cell cycle. Cell cycle phases in 75 t(12;21)-positive and 116 t(12;21)-negative ALL patients matched for age (1-10 years), immunophenotype, absence of hyperdiploidy (450 chromosomes), absence of MLL rearrangements and absence of t(9;22). Squares indicate medians, diamonds indicate 25th and 75th percentile. Cell cycle phase was measured in propidium-iodide-stained nuclei using flow cytometry.
